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Abstract
Background
Intermittent screening and treatment (IST) of malaria during pregnancy has been proposed
as an alternative to intermittent preventive treatment in pregnancy (IPTp), where IPTp is fail-
ing due to drug resistance. However, the antenatal parasitaemias are frequently very low,
and the most appropriate screening test for IST has not been defined.
Methodology/Principal Findings
We conducted a multi-center prospective study of 990 HIV-uninfected women attending
ANC in two different malaria transmission settings at Tororo District Hospital, eastern
Uganda and Colsama Health Center in western Burkina Faso. Women were enrolled in the
study in the second or third trimester of pregnancy and followed to delivery, generating
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2,597 blood samples for analysis. Screening tests included rapid diagnostic tests (RDTs)
targeting histidine-rich protein 2 (HRP2) and parasite lactate dehydrogenase (pLDH) and
microscopy, compared to nPCR as a reference standard. At enrolment, the proportion of
pregnant women who were positive for P. falciparum by HRP2/pan pLDH RDT, Pf pLDH/
pan pLDH RDT, microscopy and PCR was 38%, 29%, 36% and 44% in Uganda and 21%,
16%, 15% and 35% in Burkina Faso, respectively. All test positivity rates declined during fol-
low-up. In comparison to PCR, the sensitivity of the HRP2/pan pLDH RDT, Pf pLDH/pan
pLDH RDT and microscopy was 75.7%, 60.1% and 69.7% in Uganda, 55.8%, 42.6% and
55.8% in Burkina Faso respectively for all antenatal visits. Specificity was greater than 96%
for all three tests. Comparison of accuracy using generalized estimating equation revealed
that the HRP2- detecting RDT was the most accurate test in both settings.
Conclusions/Significance
The study suggests that HRP2-based RDTs are the most appropriate point-of-care test cur-
rently available for use during pregnancy especially for symptomatic women, but will still
miss some PCR-positive women. The clinical significance of these very low density infec-
tions needs to be better defined.
Introduction
The negative effects of malaria infection in pregnancy have been long recognized [1–4]. Placen-
tal malaria infection, while often asymptomatic, has been clearly associated with poor out-
comes including maternal anemia, low birth weight, infant mortality and delayed child
development [5–8]. Because of these dangers, the World Health Organization (WHO) recom-
mends, and many African countries implement, intermittent preventive treatment in preg-
nancy (IPTp) with sulfadoxine-pyramethamine (SP) in addition to other measures including
long-lasting insecticide-treated nets (LLINs) and effective case management. However, as SP
resistance rises, there is uncertainty over the effectiveness of SP for IPTp and alternative strate-
gies are needed [9]. The alternatives, artesunate-based combination therapy (ACT) or quinine,
are not recommended in pregnancy without first demonstrating the presence of infection.
A challenge of screening and ACT-based treatment in pregnancy is that P. falciparum
malaria parasites, sequester in the placenta and may not be detected in maternal peripheral
blood by routine laboratory testing, particularly microscopy[10]. Alternative diagnostic meth-
ods that do not rely on direct visualization of parasites may enable more reliable detection of
malaria infection during gestation. Detection of parasite antigen in peripheral blood by RDTs
offers an alternative[11]. Antigens detected by currently available RDTs include histidine-rich
protein 2 (HRP2), which persists in circulation for a number of weeks and so can accumulate,
and parasite lactate dehydrogenase (pLDH) that clears rapidly. The differing properties of
these targets may render them more or less suited as screening tests in different environments
and populations[12–13].
A prospective study was conducted to evaluate the performance of rigorously quality-con-
trolled malaria diagnostic tests during gestation and at delivery, in sites with different malaria
prevalence, to determine the potential utility of RDTs to detect and treat malaria infection dur-
ing pregnancy. This report compares results of different diagnostic tests performed on mater-
nal peripheral blood during pregnancy and at delivery.
Rapid Diagnostic Tests Accuracy during Pregnancy
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Materials and Methods
Ethics and protocol
All participants provided their written informed consent to participate in the study before any
study procedures were performed by the study staff member. When a participant could not
read and write, an impartial adult witness confirmed that the mother had participated in the
informed consent discussion, had understood the contents of the consent form, and freely
agrees to participate. Additional consent was also obtained for future use of biological samples.
The ethics committee approved this consent procedure.
The study was approved by the following ethics review committees: a) World Health Orga-
nization Research Ethics Review Committee (protocol ID RPC390), b) Comité d’Ethique Insti-
tutionnel of the Centre Muraz of the Ministère de la Santé in Burkina Faso (reference number
A23-2010/CE-CM), c) School of Medicine Research and Ethics Committee of Makerere Uni-
versity in Uganda (reference number 2011–046), and d) Uganda National Council of Science &
Technology (reference number HS160)(S1 and S2 Files). This report conforms to STROBE (S1
Table) guidelines for reporting results of observational cohort studies[14] and STARD guide-
lines for studies of diagnostic accuracy[15].
Study setting and population
The study was conducted at the Colsama health center in the District de Dô, a peri-urban area
of Bobo-Dioulasso in southwestern Burkina Faso, and at the Tororo District Hospital in south-
eastern Uganda. Both sites are government-sponsored health facilities that provide routine
antenatal and delivery care, including: provision of LLINs, provision of IPTp-SP at least twice
during pregnancy according to the standard of care at the time of the study [16], treatment of
symptomatic malaria in pregnancy with quinine (Burkina Faso) or ACTs (Uganda), and testing
and care for HIV-infected women.
Malaria transmission in the region of Bobo-Dioulasso is highly seasonal peaking from June
to October, with an estimated P. falciparum entomological inoculation rate of 300–500 infec-
tive bites per person per year [17]. Tororo region is holoendemic area for malaria, with an
entomological inoculation rate (EIR) estimated at 310 infective bites per person per year [18].
The prevalence of malaria among pregnant women in the region was reported to be approxi-
mately 40% based on PCR-corrected microscopy[19]. In both sites, P. falciparum is the domi-
nant malaria species.
Specific participant inclusion criteria were:
1. Presenting for care after quickening and before onset of labor (i.e. in the second or third tri-
mester of pregnancy)
2. Age between 16 years and 44 years
3. Willingness and ability to follow up with study visits through the duration of pregnancy and
at delivery
4. Absence of history of serious adverse reaction to sulfa-containing drugs
5. Absence of history of serious adverse reaction to artemisinin-based drugs (Uganda) or qui-
nine (Burkina Faso)
6. Absence of HIV infection
7. Absence of history of, or current, obstetric complications (e.g. pre-eclampsia, eclampsia, hyper-
tension during pregnancy, post-partum hemorrhage, current evidence of multiple gestation)
Rapid Diagnostic Tests Accuracy during Pregnancy
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8. Absence of chronic disease (including diabetes mellitus and sickle cell disease)
9. Absence of severe disease requiring inpatient management or referral
10. Provision of written informed consent
11. Absence of severe anaemia (Hb7 g/dL)
Sample size
The target sample size at each study site was calculated to test hypotheses based on the positive
and negative predictive values (PPV and NPV, respectively). The null hypothesis was: [PPV
(disease prevalence + 0.4) or NPV (1-disease prevalence)] with 80% power and 5% signifi-
cance at each study location. Previously published estimates of RDT sensitivity (65%) and spec-
ificity (98%) were used in these calculations and malaria prevalence was assumed to be 15% in
each location. Based on these estimates, an enrollment target was set of 345 women in Uganda
and 345 women in Burkina Faso, to ensure 90% confidence of obtaining the required number
of positive and negative tests, and allowing for a 15% loss to follow-up between enrolment and
delivery. To meet secondary study objectives involving clinical outcomes (not reported here), a
larger target sample size was set in Burkina Faso.
Study visits
Study activities ran from November 2010 to April 2012 at the Burkina Faso site and fromMay
2011 to April 2012 at the Uganda site. Potential participants were referred to the study team by
the antenatal clinic staff at each site; study staff completed screening and enrollment consecu-
tively, according to the selection criteria shown in Fig 1. Subsequent antenatal visits were
scheduled at least four weeks apart. Participants were encouraged to return to the study site in
case of illness between scheduled visits, and to attend the study site for delivery.
Sample collection
At each scheduled visit and at delivery, a focused physical examination was conducted and 2
mL venous blood sample was drawn for measurement of hemoglobin (Hb; HemoCue, Quest
Diagnostics, Ängelholm, Sweden), preparation of RDTs and blood smears, and storage in a
microtainer at -20°C and on filter paper. After delivery, placental blood and a placental biopsy
were collected; the complete methods and the resulting findings will be reported separately. If a
participant missed a visit then a home visit was arranged, and study staff attempted to visit the
homes of those who delivered elsewhere within 24 hours of the birth.
Provision of antenatal and delivery care
At enrollment and at each scheduled visit, RDT results were used to guide management. When
all RDT test bands were negative, the participant took a directly observed scheduled dose of
SP. When any RDT test band was positive, the participant received treatment with quinine
(600mg, eight hourly for 7 days) in Burkina Faso or artemether-lumefantrine (AL) (80/480 mg
twice daily for three days) in Uganda; the initial dose was directly observed, and the remaining
doses were given to the participant with clear instructions for completing the treatment at
home. If quinine or AL was administered, study staff visited the woman at home two weeks
later to administer a dose of SP as IPTp. If a participant presented with symptoms suggestive of
malaria, microscopy was performed immediately by study staff and microscopy results (rather
Rapid Diagnostic Tests Accuracy during Pregnancy
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Fig 1. Flow diagram of the study participants.
doi:10.1371/journal.pone.0156954.g001
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than RDT) were used for clinical management according to national policy. All study partici-
pants received routine antenatal care according to national guidelines, including receipt of a
LLIN, iron and folate supplementation, and management of any other symptoms at the treat-
ing clinician’s discretion.
Diagnostic test procedures
Rapid diagnostic tests (RDTs). RDT kits for this study were selected on the basis of their
performance in WHOmalaria RDT product testing and the target antigens detected[20]. The
study selected the three most commonly used antigen-detection targets: HRP2, pan-specific
pLDH (pan-pLDH) and P. falciparum-specific pLDH (Pf-pLDH). Two combination tests com-
prising four test bands were used: CareStart™Malaria pLDH (Pf/PAN) Test, product G0121,
lot E10IL, expiry April 2012 (here referred a pLDH); and CareStart™Malaria HRP2/pLDH
(Pf/PAN) COMBO Test, product G0131, lot E10IR, expiry April 2012 (here referred a HRP2).
RDTs were procured directly from the manufacturer, Access Bio, Inc. (Monmouth Jct, New
Jersey, USA).
Before the study began, RDTs passed lot testing according to WHO-FIND guidelines[20] at
the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. At the study
sites, temperature and humidity of the storage areas for RDTs were not controlled but were
monitored and remained within the manufacturer’s recommended storage conditions of 4°C
to 40°C. After the completion of participant follow-up, RDTs were retrieved from both sites
and again subjected to lot performance testing at the CDC.
RDTs were performed on maternal venous blood according to manufacturers’ instructions.
Results of all four test bands were recorded. Invalid RDT results were repeated using the same
blood sample. RDT results were reported to the treating clinician to guide participant manage-
ment according to the study protocol.
Microscopy. Thick and thin blood smears were prepared and stained with 2% Giemsa for
30 minutes. A smear was declared negative if examination of 100 high power fields did not
reveal asexual parasites or gametocytes. For positive smears, parasite density was calculated by
counting the number of asexual parasites per 200 leukocytes (or per 500, if the count is<10
asexual parasites/200 leukocytes), assuming a leukocyte count of 8,000/μl. When a thick smear
was positive, the corresponding thin blood smear was read to determine the parasite species.
Each smear was read by two microscopists who were blinded to the RDT results and any previ-
ous microscopy. Results were considered discordant if one result was negative and the other
positive for malaria infection; for positive smears, if the density estimates differed by>50% of
the maximum reading; or if the two microscopists reported different species present. Discor-
dant results were resolved by a third microscopist, taking into account concordance with the
initial readings[21].
Before the study began, all microscopists were pre-qualified using WHO slide banks and
procedures [22] and required to reach Level 1 or 2 expertise level. In addition, a random sample
of 10% of slides from each site was sent for review at University of Lagos by Level 1 expert
microscopists.
Polymerase Chain Reaction (PCR). For all routine antenatal visits, 2.5 mL of peripheral
blood was collected into an EDTA microtainer, labeled and stored at -20°C. Stored samples
were transferred to a central laboratory (at Institut de Recherche en Sciences de la Santé [IRSS]
in Bobo-Dioulasso, Burkina Faso) and analyzed by nested PCR to confirm presence or absence
of parasites, and parasite species. PCR procedures were performed according to standardized
protocols and published methods[23]. PCR technologists were blinded to RDT and microscopy
results.
Rapid Diagnostic Tests Accuracy during Pregnancy
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Before the study began, proficiency testing of the IRSS molecular laboratory was performed
using reference samples from the CDC. In addition, a stratified random sample of 5% of sam-
ples were re-tested at the Institut Pasteur du Cambodge laboratory in Phnom Penh, Cambodia,
as a means of external quality control.
Data management and statistical analysis
Test outcomes and clinical data were collected on case record forms and were double-entered
in an electronic database using Epi-Info version 6.04 (Centers for Disease Control and Preven-
tion, Atlanta, GA). Data were subsequently cleaned and analyzed using SPSS version 16.0. Data
from the antenatal visits (655 samples from Uganda and 1087 samples from Burkina Faso)
were used to calculate sensitivity, specificity, positive predictive value (PPV) and negative pre-
dictive value (NPV) for each diagnostic test. Generalized Estimating Equations (GEEs) were
used to compare the sensitivity, specificity, PPV and NPV between diagnostics, assuming that
PCR is the gold standard for the presence of P. falciparum. Explanatory variables including
age, gravidity, prior antimalarial treatment or IPTp, fever symptoms within last 24 hours, were
tested for their influence on diagnostic performance.
Results
Study participants baseline demographics
Six hundred and fifty (650) pregnant women in Burkina Faso and 340 in Uganda were enrolled,
of whom 85% and 90% respectively returned for delivery (Fig 1). Half received their first IPTp-
SP dose beyond 28 weeks of amenorrhea in Burkina Faso, while this proportion was three
quarters in Uganda. Other baseline characteristics and comparisons between the two sites are
shown in Table 1.
Diagnostic test results
The two different RDTs containing HRP2/pan pLDH RDT is hereby referred to as HRP2 kit
and the second kit containing Pf pLDH/pan pLDH RDT is reported as pLDH for ease of read-
ing. At enrolment in Burkina Faso, the proportion of samples positive based on PCR for P. fal-
ciparum35%, HRP2 RDT 21% Pf pLDH 16% RDT and expert microscopy 15%. In Uganda
these proportions were 44% for PCR, 38% for HRP2, 29% pLDH and 36% microscopy
(Table 2). The proportions positive for all diagnostics test were lower for subsequent and deliv-
ery samples at each site. Overall PCR and the HRP2 based RDT detected more infections than
the Pf-pLDH/pan pLDH RDT and expert microscopy. Considering the individual test bands of
each RDT, the pan pLDH test band returned fewer positive results than either the HRP2 or Pf
pLDH test bands. In Burkina Faso the pan pLDH band was positive in 76% and 12% of positive
RDT results for the HRP2/pan pLDH RDT and the Pf pLDH/pan pLDH RDT, respectively. In
Uganda these values were 84% and 37%.
Seasonal patterns in test positivity at enrollment are shown in S1 Fig. The graph shows vari-
ation in PCR-detected infection in Burkina Faso from just under 20% at the end of the dry sea-
son to about 55% toward the end of the rainy season; and a similar range in Uganda.
P. falciparum was the predominant species at both sites across all visits as determined by
PCR (Table 2). In Burkina Faso, the majority of samples (275, 97%) contained P.falciparum,
while 3% were mono-infections with P. ovale. In Uganda P. falciparum was found in 95% of
samples, either alone (84%) or in combination with P. ovale or P.malariae. PCR-determined
mono-infection with P. ovale and P.malariae were recorded for 9 samples from Burkina Faso
and 13 samples from Uganda. Neither of the RDTs used returned positive results for these
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samples. Further analysis is restricted to consideration of P. falciparum only (including mixed
infections).
Estimates of parasite density at enrolment were obtained from microscopy readings. In Bur-
kina Faso 95/650 (14.6%) of women were parasite positive by microscopy. For this group of
women the geometric mean parasite density was 788 parasites/μL (median = 780 parasites/μL,
IQR = 279.5–2,349 parasites/ μL). Thirty-six percent (123/340) of women in Uganda were
parasite positive by microscopy at enrolment. For this group of women the geometric mean
parasite density was 371 parasites/μL (median = 348 parasites/μL, IQR = 72–1,508 parasites/
μL). Although a smaller proportion of women were microscopically positive at enrolment in
Table 1. Demographic characteristics of enrolled pregnant women from antenatal clinics in Tororo District Hospital, Uganda and Colsama Health
Center, Burkina Faso.
Demographic characteristic Burkina Faso N = 650 Uganda N = 340 Comparison of sites
Age: median (IQR) 24 (20–29) 23 (20–27) P = 0.001*
Gravidity: median (IQR) 3 (1–4) 2 (1–3)
Primigravidae 170 (26.2%) 115 (33.8%) P = 0.012*
Fundal height cm- median(IQR) 23 (21–25) 24 (20–27)
Participants with fever symptoms 68 (10.5%) 47 (14.0%)
Prior IPTp at enrolment (n, %) 107 (16.5%) 39 (11.5%) P = 0.038*
Prior antimalarial treatment 199 (30.6%) 43 (12.6%) P = 0.001*
* statistically signiﬁcant difference between the two study populations (distributions by Mann-Whitney U test, proportions by chi square test)
doi:10.1371/journal.pone.0156954.t001
Table 2. Diagnostic test results and species of samples of pregnant women from Burkina Faso and
Uganda.
Number (%, n) of positive results
Burkina Faso Uganda
Enrolment Visits
Pf PCR 224 (34.5%, 649) 149 (44.0%, 338)
HRP2/pan pLDH RDT 134 (20.6%, 650) 130 (38.2%, 340)
Pf pLDH/pan pLDH RDT 102 (15.7%, 650) 99 (29.1%, 340)
Microscopy 95 (14.6%, 650) 123 (36.2%, 340)
Subsequent visits
Pf PCR 25 (5.7%, 438) 70 (22.1%, 317)
HRP2/pan pLDH RDT 11 (2.5%, 438) 54 (17.0%, 317)
Pf pLDH/pan pLDH RDT 7 (1.6%, 438) 40 (12.6%, 317)
Microscopy 7 (1.6%, 437) 43 (13.6%,317)
Delivery visit
Pf PCR 26 (5.7%, 555) 88 (29.7%, 296)
HRP2/pan pLDH RDT 9 (1.6%, 555) 67 (22.9%, 297)
Pf pLDH/pan pLDH RDT 9 (1.6%, 555) 39 (13.3%, 297)
Microscopy 9 (1.6%, 554) 49 (16.7%, 294)
Species distribution of all PCR-positive samples
P. falciparum 264 (93.0%) 272 (84.0%)
P. ovale 9 (3.2%) 9 (2.8%)
P.malariae 0 8 (2.5%)
Mixed (Pf. + other) 11 (3.9%) 35 (10.8%)
Total samples +ve by PCR 284 324
doi:10.1371/journal.pone.0156954.t002
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Burkina Faso compared to Uganda, these women presented with higher parasite densities
(P = 0.002, Mann-Whitney test).
At enrolment, 68/650 (10.5%) of participants had fever symptoms in Burkina Faso. There
was no association between having febrile symptoms and returning at least one positive diag-
nostic tests (P = 0.894, Fisher’s Exact test). In Uganda, 47/340 (13.8%) of participants had fever
symptoms and these participants were more likely to return at least one positive diagnostic
result, compared to participants without febrile symptoms (P<0.001, Fisher’s Exact test).
At enrollment, 15% and 41% of positive samples were positive only by PCR in Uganda and
Burkina Faso, respectively. However, among the subsequent visit and delivery visit samples the
proportion of samples that were positive by PCR only increased to 25% and 27% in Uganda,
and to 55% and 58% in Burkina Faso, respectively. Therefore, the proportion of sub-patent
infections—i.e. infections below the level of detection of RDTs and microscopy but positive by
PCR—was higher at subsequent and delivery visits than at enrollment visits (S1 Fig).
Diagnostic test results compared with PCR as reference standard
In the antenatal samples from Burkina Faso, the HRP2 had a significantly higher sensitivity for
P. falciparum than either microscopy or the Pf-pLDH/pan pLDH RDT (P<0.01; Table 3).
There was no difference between the sensitivities of microscopy and the pLDH (p>0.1). Speci-
ficity values on these same samples were high (>99%) with no significant differences between
the three diagnostic tests (P>0.3, Table 3). There were also no differences between the PPV of
the three diagnostics (P = 0.085, Table 3). Considering NPV, microscopy and the Pf-pLDH/
pan pLDH RDT had similar values (P = 0.194), while the HRP2had a significantly higher NPV
for P. falciparum (P<0.001).
In Uganda, the sensitivity and NPV of the HRP2on antenatal samples were significantly
higher than expert microscopy, which were significantly higher than the pLDH (P<0.02,
Table 3). The specificities for the three tests were above 95%, however the HRP2had a
Table 3. Accuracy of diagnostics for detection of P. falciparum in peripheral maternal blood during antenatal visits and delivery visits.
Burkina Faso (PCR positive 249 / 1087) Statistic (95% CI) Uganda (PCR positive = 218 / 655) Statistic (95% CI)
Microscopy HRP2/pan pLDH
RDT
Pf pLDH/pan pLDH
RDT
Microscopy HRP2/pan pLDH
RDT
Pf pLDH/pan pLDH
RDT
Antenatal
visits
Sensitivity 39.8 (34.1–46.3) 55.8 (50.0–62.4) 42.6 (36.9–49.2) 69.7 (63.9–
76.1)
75.7 (70.2–81.6) 60.1 (53.9–67.0)
Speciﬁcity 99.8 (99.1–99.9) 99.3 (98.4–99.7) 99.6 (98.9–99.9) 98.4 (96.7–
99.2)
95.7 (93.3–97.2) 98.2 (96.4–99.1)
PPV (%) 98.0 (92.2–99.5) 95.9 (90.9–98.1) 97.3 (91.6–99.1) 95.6 (90.9–
97.9)
89.7 (84.2–93.3) 94.2 (87.7–97.1)
NPV (%) 84.8 (82.3–86.8) 88.3 (86.1–90.2) 85.4 (83.0–87.4) 86.7 (83.3–
89.4)
88.6 (85.5–91.3) 83.1 (79.6–86.1)
Delivery visit
Sensitivity (%) 34.6 (20.4–58.7) 34.6 (20.4–58.7) 34.6 (20.4–58.7) 54.0 (44.5–
65.6)
67.0 (57.9–77.6) 42.1 (32.9–53.7)
Speciﬁcity (%) 100.0 (99.3–
100.0)
100.0 (99.3–100.0) 100.0 (99.3–100.0) 99.5 (96.6–
99.9)
96.2 (92.4–98.1) 99.0 (96.2–99.8)
PPV (%) 100.0 (66.2–
100.0)
100.0 (66.2–100.0) 100.0 (66.2–100.0) 97.9 (85.5–
99.7)
88.1 (77.1–93.8) 94.9 (80.2–98.7)
NPV (%) 96.9 (95.0–98.1) 96.9 (95.0–98.1) 96.9 (95.0–98.1) 84.7 (80.4–
89.6)
86.0 (81.8–90.4) 81.7 (77.0–86.7)
doi:10.1371/journal.pone.0156954.t003
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significantly lower value than the other two diagnostics (P<0.05, Table 3). The HRP2 kit had
the lowest PPV of 89.7%. This value was significantly lower than microscopy (P = 0.006), but
was not significantly different to the pLDH (P>0.05, Table 3).
Both RDTs returned false positive results for P. falciparum infection using PCR as the refer-
ence standard. In Burkina Faso the false positive rates (false positives/all positives) were 0.24%
and 0.06% for the HPR2/pan pLDH RDT and pLDH respectively (n = 1639). In Uganda the
false positive rates were higher at 2.22% and 0.63%, respectively (n = 948). Interestingly, one
enrolment sample in Uganda was positive on both RDTs, but negative by PCR and microscopy.
There was no pattern in the false positive rates between enrolment, subsequent visit and deliv-
ery samples. There were no false positive results for microscopy.
Factors associated with test accuracy on antenatal samples
Data from the antenatal samples in Uganda and Burkina Faso were merged to investigate fac-
tors that affected the diagnostic performance of microscopy, and the two RDTs. At total of
1,742 samples were available for analysis in this combined data set and the factors considered
were age of woman, gravidity, whether the women had received prior antimalarial treatment or
IPTp during the pregnancy, whether fever symptoms where present or reported within 24
hours of the sample collection, and country. Country interactions were also considered. The
temporal pattern of transmission differed between Uganda and Burkina Faso so month of visit
was not included in the models as an explanatory variable. Hence the effect of seasonality was
not assessed in the combined data set (Table 4). The rainy season in Burkina Faso is between
Table 4. Fitted models predicting diagnostic performance on antenatal samples in Uganda and Burkina Faso.
Parameter Explanatory variable Relative Risk for explanatory variable (95% CI)
Microscopy HRP2 / pan(pLDH) RDT Pf pLDH / pan(pLDH) RDT
Sensitivity Baseline value* 91.8% 92.0% 74.2%
Gravidity 0.85 (0.80–0.91) 0.90 (0.85–0.94) 0.83 (0.77–0.90)
Prior trmt No 1.00 1.00 1.00
Yes 0.80 (0.69–0.93) 0.87 (0.77–0.98) NS
Country Uganda 1.00 1.00 1.00
Burkina Faso 0.61 (0.52–0.72) 0.77 (0.69–0.87) 0.78 (0.66–0.92)
Speciﬁcity Baseline value* 97.3% 91.1% 96.0%
Age NS 1.13 (1.02–1.25) NS
Prior trmt No 1.00 1.00 1.00
Yes 16.13 (1.98–125.00) 3.00 (1.42–6.33) 10.75 (2.79–41.67)
Symptoms No 1.00 1.00 1.00
Yes 0.18 (0.05–0.65) 0.25 (0.12–0.52) 0.28 (0.08–0.97)
Country Uganda 1.00 1.00 1.00
Burkina Faso 4.85 (1.00–23.26) 5.32 (2.20–12.82) 4.41 (1.16–16.67)
Negative Predictive Value Baseline value* 75.6% 80.8% 72.9%
Age 1.04 (1.00–1.07) 1.04 (0.99–1.08) 1.05 (1.02–1.09)
Gravidity 0.88 (0.80–0.98) 0.87 (0.78–0.98) 0.86 (0.78–0.94)
Prior trmt No 1.00 1.00 1.00
Yes 2.87 (2.23–3.69) 2.84 (2.11–3.82) 3.10 (2.43–3.96)
Country Uganda 1.00 1.00 1.00
Burkina Faso NS NS NS
* Estimated marginal mean of parameter for woman in Uganda who is primigravidae, aged 20 years, has had no prior treatment and has no fever symptoms.
NS, Not signiﬁcant (P>0.05)
doi:10.1371/journal.pone.0156954.t004
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June and October. Uganda has two rain seasons, December to February and again between
May to July.
Sensitivity. The sensitivity of all three diagnostics was significantly influenced by gravidity
(P<0.05), while prior treatment/IPTp was important for microscopy and the HRP2 (P<0.05),
but not the pLDH (P>0.05). Sensitivity decreased with increasing gravidity, and also with
prior treatment/IPTp. Country was a significant factor for sensitivity for all diagnostics
(P<0.05), even after accounting for gravidity and prior treatment/IPTp, with Uganda having
higher sensitivity than Burkina Faso.
Specificity. For all three diagnostics, specificity was significantly influenced by prior treat-
ment/IPTp, the presence of fever symptoms and country (P<0.05). The presence of fever
symptoms and/or having no prior treatment/IPTp was associated with lower specificity. For
the HRP2, age of woman was also a significant explanatory variable (P<0.05); specificity
increased with age.
Positive Predicative value. None of the explanatory variables tested were significant in
the model to predict PPV (P>0.05).
Negative Predicative Value. Age, gravidity and prior treatment/IPTp were found to influ-
ence the NPV in all three diagnostics (P<0.05). The largest influencing factor was prior treat-
ment/IPTp, with samples from women having prior treatment/IPTp having a higher NPV. The
influence of age and gravidity was most obvious in samples from women who had no prior
treatment/IPTp with increasing age and decreasing gravidity associated with higher NPV. For
the samples collected in Burkina Faso, month of visit was also a significant factor for NPV for
all three diagnostics, with lower NPV in the high transmission season (Oct-Jan).
Parasite Density. The diagnostic positivity rate for the different tests on enrolment sam-
ples was influenced by parasite density. The number of diagnostic tests positive for a sample
increased with increasing parasite density (P<0.001, Mann-Whitney U test). All samples with
a microscopy-determined density above 1,000 parasites/μL were positive on at least three of
the diagnostic tests.
Discussion
Malaria diagnostic testing of pregnant women may allow better targeting of efficacious antima-
larial treatment to asymptomatic women with demonstrated malaria infection, as a replace-
ment for failing IPTp. In this study, we screened asymptomatic pregnant women with quality-
assured RDTs in two African clinical settings (Uganda, high transmission, and Burkina Faso,
seasonal transmission) and treated those with positive results. In parallel, microscopy and PCR
were conducted. We determined the accuracy of the various diagnostics using PCR as the refer-
ence standard in these two distinct settings. Diagnostic testing of pregnant women who receive
IPTp detected high proportions of malaria infection. Many of these infections were of low den-
sity and only detected by PCR, rather than HRP2/pan pLDH and Pf pLDH/pan pLDH RDTs
and microscopy.
Close to half of all the women in the higher transmission setting had detectable malaria
infection but only 14% reported fever or history of fever symptoms at the time of enrolment. In
the seasonal transmission setting, fewer (35%) women had detectable parasites at enrolment,
with 10% reporting fever or history of fever. Overall, PCR detected 32%, 49% and 47% more
positive samples then the HPR2/pan pLDH RDT, the pLDH and expert microscopy, respec-
tively. The higher sensitivity of the HRP2-detecting RDT may reflect the detecting of circulat-
ing antigen from parasites confined to the placenta, or recent spikes in parasite density. While
it is reasonable to postulate that higher parasite densities in circulation may cause greater harm
to mother and child, a greater understanding of the clinical significance of the third of PCR-
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positive women who were undetectable by the most sensitive RDT (and so would not receive
treatment under a RDT-based screening approach) is needed.
Age, gravidity, fever symptoms, prior antimalarial treatment or IPTp, and month of visit
were all significant explanatory factors for variations in sensitivity, specificity, PPV, NPV,
although the significance of associations varied with diagnostic test and country. The lower
prevalence of infection in older and more gravid women likely reflects increasing immunity,
though the differences in prevalence in this age range should be relatively low. As expected, all
three point- of-care diagnostics were of high sensitivity and lower specificity in women with
fever symptoms—these cases are expected to have higher parasite density. Parasite density is
known to influence the performance of malaria diagnostics; however, parasite density itself was
not assessed as a factor in the statistical models since densities were only available for micros-
copy-positive samples. The presence of fever symptoms and prior treatment/IPTp were also
used as surrogate measures for parasite density. The association between the explanatory vari-
ables and diagnostic performance suggests that some measures of performance are significantly
influenced by immunity and parasite density. The significant country effect for sensitivity and
specificity is likely linked to infection rates, as the Ugandan site has a higher incidence and
multi-clonal infections and recrudescence of infection is probably greater, promoting higher
parasite loads. Transmission in Burkina Faso is highly seasonal which was shown to impact on
NPV, but seasonality itself did not affect PPV, sensitivity or specificity. These results indicate
that the epidemiological background and source of samples are important considerations when
diagnostic performance is being assessed. Of particular interest for antenatal screening are the
differences noted for prior treatment/IPTp. It may be that prior treatment/ IPTp was fre-
quently successful in clearing infection, and these patients, when positive, tended to have new
infections with higher parasite densities, and so were more readily detectable.
The advantage of HRP2-detecting RDTs over microscopy, presumably reflecting the detec-
tion of sequestration of parasites in the placenta, is contrary to what some previous studies
have reported [24]. In this study we believe microscopy was of very high quality, and expert
microcopy conducted in Uganda was approximately similar to the HRP2 in the proportion of
positive samples; and expert microscopy in Burkina Faso was approximately similar to the Pf-
pLDH/pan pLDH RDT. However, these levels of expert reading are not available for daily
health care in antenatal setting, and it is likely that microscocpy-based point-of-care screening
at antenatal visits would commonly be poorer when performed on a routine basis.
False positive (FP) rate was higher in HRP2 than pLDH RDTs, but the reason for this is not
clear in the absence of prior treatment. Other previous studies showed that the difference was
due to persistent antigenicity [25]. However, since the FP rate was lower post –treatment, this
suggests it may not be persistent HRP2 antigenicity, but actually true positives missed by the
reference test (PCR).
While evidence is lacking as to whether the 25–50% RDT-missed PCR-positive infections
are clinically significant [26], many stakeholders may consider these RDTs insufficiently sensi-
tive for effective use in antenatal screening programs. However, in many areas, declining
malaria transmission and/or increasing SP resistance may force a change in IPTp strategies as
it becomes difficult to justify or ineffective. Currently, achieving greater sensitivity requires the
use of a nucleic acid amplification test (NAAT) assay, at significantly greater cost, and the clini-
cal benefit may be small. As IPTp is reduced, programmes will have to make this cost-benefit
trade-off. A recent study showed that by improving the diagnostic sensitivity to 20 parasites
per microlitre increased the proportion of detection of infection by 49% in Burkina Faso[27].
Screen testing for malaria during the first antenatal visit detected the highest proportion of
parasite infections, and at fairly similar levels in both Burkina Faso and Uganda. Infection rates
reduce greatly after initial screening by RDT and treatment. This suggests that a screen and
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treat approach may be an effective alternative to IPTp, however the study design which
included IPTp could not exclude the possibility that the reduction in prevalence was due, at
least in some part, to the IPTp. However, the drop in infection rates in subsequent visits, indi-
cating the impact of IPTp and treatment, was far greater in the seasonal malaria setting of Bur-
kina Faso than in Tororo in Uganda where transmission is high and perennial. This likely
reflects both rapid re-infection and higher rates of SP resistance /poorer prophylactic effect in
Uganda.
The strengths of this study were the rigorous quality control of diagnostic methods and test-
ing. Additionally, the prospective study design allowed us to observe pregnancy over time. The
administration of IPTp to women 2 weeks after treatment, an ethical requirement, made it dif-
ficult to separate the impact of screening and treatment of confirmed cases from any beneficial
effects of IPTp. Detailed clinical and histopathological assessment and longer follow-up post-
delivery would inform the impact of the infections missed by RDT. Further data analysis from
the study will assess this.
Conclusions
The HRP2-based RDT appeared to perform better than Pf pLDH-based RDT and expert
microscopy, in detecting malaria infection. All three diagnostics failed to detect some infections
which were positive by PCR. Infection rates reduce greatly after initial screening by RDT and
treatment. This suggests that a screen and treat approach may be an effective alternative to
IPTp. Although HRP2 is not perfect, this study provides robust data on performance to inform
decisions/tradeoffs in future setting like in lower transmission. Our results may inform policy
decisions on alternatives to IPTp, especially in areas where declining malaria transmission and/
or increasing SP resistance force a change.
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